Immupharma plc

Anifrolumab update positive for lupus field – while ImmuPharma’s LupuzorTM could represent a highly successful product

The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announced an update report on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. Summary highlights of the update include: AstraZeneca (LON: AZN) announced …